Dapsone interactions
Medicines
394 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Articaine Hydrochloride + Epinephrine Bitartrate | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Major | Synergy · Unknown | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms | 9 sources — open the full entry |
| Benzocaine + Butamben + Tetracaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 12 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride + Dextrose | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 9 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Hydrocortisone + Lidocaine | Major | Synergy · Unknown | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 5 sources — open the full entry |
| Lidocaine + Adrenaline | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Epinephrine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Prilocaine | Major | Synergy | Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite. Coadministration with other oxidizing agents that can also induce…3 documented mechanisms | 18 sources — open the full entry |
| Lidocaine HydrochlorideInjectionSpray | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Ofloxacin + Clotrimazole + Beclomethasone + Lidocaine | Major | Synergy · Unknown | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms | 5 sources — open the full entry |
| Ropivacaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Tolperisone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Tropicamide + Phenylephrine + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Activated Charcoal | Moderate | Absorption | Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects… | 25 sources — open the full entry |
| Adalimumab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Alpelisib | Moderate | Metabolism | Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin… | 36 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 2C9 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with bosentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 and/or 3A4 isoenzymes. The mechanism is… | 5 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with ceritinib may increase the plasma concentration and the risk of adverse effects of drugs that are substrates of CYP450 2A6 and/or 2E1… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Synergy · Unknown | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…2 documented mechanisms | 7 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Synergy · Unknown | Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other…2 documented mechanisms | 7 sources — open the full entry |
| Cisplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Colchicine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Crizotinib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Diltiazem Hydrochloride | Moderate | Metabolism | Coadministration with diltiazem may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased… | 11 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Efavirenz | Moderate | Metabolism | Coadministration with efavirenz may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated… | 2 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp)… | 4 sources — open the full entry |
Conditions
Conditions in which Dapsone needs care, as documented in this source.
Bone Marrow Failure Disorders
MajorThe use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias. Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia). Monitoring for hematologic abnormalities is recommended.
12 sources
- Laing A "Unusual reaction to intramuscular sulfone in two leprosy patients in malaysia." Int J Lepr 48 (1980): 70
- McConkey B "Adverse reactions to dapsone." Lancet 2 (1981): 525
- Cook I, Kish M "Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine." Med J Aust 143 (1985): 139-41
- Potter M, Yates P, Slade R, Kennedy C "Agranulocytosis caused by dapsone therapy for granuloma annulare." J Am Acad Dermatol 20 (1989): 87-8
- Hornsten P, Keisu M, Wiholm B "The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988." Arch Dermatol 126 (1990): 919-22
- Duhra P, Charles-Holmes R "Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia." Br J Dermatol 125 (1991): 172-4
- Kraus A, Jakez J, Palacios A "Dapsone induced sulfone syndrome and systemic lupus exacerbation." J Rheumatol 19 (1992): 178-9
- "Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company (2022):
Show all 12 sourcesShow fewer sources
- Cockburn EM, Wood SM, Waller PC, Bleehen SS "Dapsone-induced agranulocytosis: spontaneous reporting data." Br J Dermatol 128 (1993): 702-3
- Woodbury GR, Jr Fried W, Ertle JO, Malkinson FD "Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis." J Am Acad Dermatol 28 (1993): 781-3
- Meyerson MA, Cohen PR "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus." Mayo Clin Proc 69 (1994): 1159-62
- Raizman MB, Fay AM, Weiss JS "Dapsone induced neutropenia in patients treated for ocular cicatricial pemphigoid." Ophthalmology 101 (1994): 1805-7
Liver Diseases
ModerateThe use of dapsone has been associated with the development of hyperbilirubinemia. Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia. Monitoring liver function is recommended and discontinuation of the drug may be necessary.
5 sources
- May DG, Arns PA, Richards WO, et al. "The disposition of dapsone in cirrhosis." Clin Pharmacol Ther 51 (1992): 689-700
- Fleming CM, Branch RA, Wilkinson GR, Guengerich FP "Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4." Mol Pharmacol 41 (1992): 975-80
- Mills J, Leoung G, Ileana M, Hopewell PC, Hughes WT, Wofsy C "Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Antimicrob Agents Chemother 32 (1988): 1057-60
- "Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company (2022):
- Beumont MG, Graziani A, Ubel PA, Macgregor RR "Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole." Am J Med 100 (1996): 611-6
Therapeutic duplication
Drug classes that overlap with Dapsone, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antipneumocystis agents
The recommended maximum number of medicines in the 'antipneumocystis agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antipneumocystis agents' category.
Example product in the source data (US market): Sulfamethoxazole/trimethoprim